Efficacy and dosing issues of novel antipsychotics

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 1, 1998, Pages

  Wirshing, W C ^a   Marder, S R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; SEDATIVE AGENT;

ARTICLE; COGNITION; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0031961233     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739-45.
2. Chouinard G, Jones B, Remington G et al (1993) A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychophannacol 13: 25-40.
3. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-35.
4. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-26.
5. Beasley CM, Tollefson G, Tran P et al (1996) Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 14: 111-23.
6. Beasley CM, Sanger T, Satterlee W et al (1996) Olanzapine versus placebo: Results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 124: 159-67.
7. Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: Results of an international collaborative trial. Am J Psychiatry 154: 457-65.
8. Small JG, Hirsch SRA, Miller BG et al (1997) Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-57.
9. Borison RL, Arvanitis LA, Miller BG, Group TUSS (1996) ICI 204,638, an atypical antipsychotic: Efficacy and safety in a multi-center placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-69.
10. Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-46.
11. Zimbroff D, Kane J, Tamminga CA et al (1997) Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry. 154: 782-91.
12. Marder SR, Davies JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 58: 538-46.
13. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10: 207-13.
14. Tollefson GD, Sanger TM (1997) Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-74.
15. Möller H-J, Müller H, Borison RL et al (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: A reevaluation of the North-American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45-9.
16. Blin OA, Azoprin A, J-M, Bouhours P (1996) Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 16: 38-44.
17. Jeste DV, Klausner M, Brecher M et al (1997) A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial. Psychopharmacol 131: 239-47.
18. Bondolfi G, Baumann P, Patris M et al (1998) Risperidone versus clozapine in treatment - resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry [in press].
19. Wirshing WC (1996) Treatment resistant schizophrenia: handling the switch. Schizophr Rev 4: 7-8.
20. Alvir JM, Lieberman JA, Safferman AZ et al (1993) Clozapine induces agranulocytosis: Incidence and risk factors in the United States. N Engl J Med 329: 162-7.
21. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Ain J Psychiatry 153: 321-30.
22. Goldberg TE, Weinberger DR (1996) Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 57: 62-5.
23. Tune LA, Strausse ME, Lew MF et al (1982) Serum levels of anticholinergic drugs and impaired recent memory in schizophrenia patients. Am J Pyschiatry 139: 1460-2.
24. Calev A (1983) Anticholinergic drugs and memory. Br J Psychiatry 143: 422-3.
25. Perlick D, Stastny P, Katz I et al (1986) Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 143: 230-2.
26. Gelenberg AJ, Van Putten T, Lavori PW et al (1989) Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 9: 180-5.
27. McEvoy JP (1987) A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 48: 20-3.
28. Gallhofer B, Bauer U, Lis S et al (1996) Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6: S13-S20.
29. Gallhofer B, Bauer U, Gruppe H et al (1996) First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 2: 16S-24S.
30. Green MF, Marshall BDJ, Wirshing WC et al (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799-804.
31. Slip E, Lussier I (1996) The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 41: 35S-40S.
32. Amery W, Marder SR (1998) Safety and switching issues of novel antipsychotics. Int J Psychiatry Clin Pract (suppl 1) S43-49.